Vor Biopharma (VOR) Stock Price, News & Analysis

Company Overview

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.76 to $0.81
• 50-Day Range: $0.64 to $1.05
• 52-Week Range: $0.63 to $3.14
• Volume: 208,334 shs
• Average Volume: 619,895 shs
• Market Capitalization: $54.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.36
• Consensus Rating: Buy

Vor Biopharma Stock Analysis - MarketRank™

Vor Biopharma scored higher than 34% of companies evaluated by MarketBeat, and ranked 780th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vor Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vor Biopharma has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vor Biopharma are expected to grow in the coming year, from ($1.55) to ($1.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vor Biopharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vor Biopharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for VOR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vor Biopharma does not currently pay a dividend.

Dividend Growth

Vor Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for VOR.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

10 people have searched for VOR on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vor Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.70% of the stock of Vor Biopharma is held by insiders.

Percentage Held by Institutions

97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VOR Stock Analysis - Frequently Asked Questions

How have VOR shares performed this year?

Vor Biopharma's stock was trading at $2.25 at the beginning of the year. Since then, VOR stock has decreased by 64.7% and is now trading at $0.7948.
View the best growth stocks for 2024 here.

How were Vor Biopharma's earnings last quarter?

Vor Biopharma Inc. (NYSE:VOR) announced its earnings results on Thursday, November, 7th. The company reported ($0.40) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.40).

When did Vor Biopharma IPO?

Vor Biopharma (VOR) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel served as the underwriters for the IPO.

Who are Vor Biopharma's major shareholders?

Vor Biopharma's top institutional shareholders include Exchange Traded Concepts LLC (0.24%) and Rosalind Advisors Inc. (0.11%).
View institutional ownership trends.

How do I buy shares of Vor Biopharma?

Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Vor Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vor Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Ford Motor (F), Pfizer (PFE), Bank of America (BAC) and General Motors (GM).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/19/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:VOR
• CUSIP: N/A
• CIK: 1817229
• Web: www.vorbiopharma.com
• Phone: 617-655-6580
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.36
• High Stock Price Target: $17.50
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +1,328.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 68,670,000
• Free Float: 65,446,000
• Market Cap: $54.58 million
• Optionable: Not Optionable
• Beta: -0.40